| Zhang Hua,Yu Jingping,Ni Xinchu,et al.Long-term survival analysis of thalidomide combined with radiotherapy for patients with esophageal carcinoma[J].Chinese Journal of Radiological Medicine and Protection,2015,35(6):437-440 |
| Long-term survival analysis of thalidomide combined with radiotherapy for patients with esophageal carcinoma |
| Received:February 26, 2015 |
| DOI：10.3760/cma.j.issn.0254-5098.2015.06.008 |
| KeyWords:Esophageal cancer Radiotherapy Vascular endothelial growth factor Thalidomide |
| FundProject:江苏省卫生厅指导性科研项目(Z201220);常州市卫生局重大项目(ZD201105);常州市科技支撑社会发展项目(CE20125021) |
| Author Name | Affiliation | E-mail | | Zhang Hua | Department of Radiotherapy, the Changzhou Second People's Hospital, Affiliated Hospital of Nanjing Medical University, Changzhou 213003, China | | | Yu Jingping | Department of Radiotherapy, the Changzhou Second People's Hospital, Affiliated Hospital of Nanjing Medical University, Changzhou 213003, China | | | Ni Xinchu | Department of Radiotherapy, the Changzhou Second People's Hospital, Affiliated Hospital of Nanjing Medical University, Changzhou 213003, China | | | Wang Jian | Department of Radiotherapy, the Changzhou Second People's Hospital, Affiliated Hospital of Nanjing Medical University, Changzhou 213003, China | | | Jin Jianhua | Department of Radiotherapy, the Changzhou Second People's Hospital, Affiliated Hospital of Nanjing Medical University, Changzhou 213003, China | | | Zhu Qi | Department of Radiotherapy, the Changzhou Second People's Hospital, Affiliated Hospital of Nanjing Medical University, Changzhou 213003, China | | | Deng Linghui | Department of Radiotherapy, the Changzhou Second People's Hospital, Affiliated Hospital of Nanjing Medical University, Changzhou 213003, China | | | Sun Zhiqiang | Department of Radiotherapy, the Changzhou Second People's Hospital, Affiliated Hospital of Nanjing Medical University, Changzhou 213003, China | | | Sun Suping | Department of Radiotherapy, the Changzhou Second People's Hospital, Affiliated Hospital of Nanjing Medical University, Changzhou 213003, China | ssp56@126.com |
|
| Hits: 3463 |
| Download times: 2621 |
| Abstract:: |
| Objective To study effect of thalidomide on the long-term survival outcome of esophageal carcinoma with radiotherapy by reducing serum vascular endothelial growth factor (VEGF) levels. Methods A total of 81 inoperable esophageal cancer patients were divided into two groups according to serum VEGF levels during radiotherapy: treatment group (thalidomide) with 32 patiens and untreatment group with 49 patients. Overall survival (OS) and progression free survival (PFS) were analyzed for these two groups. Twenty patients whose VEGF level decreased after thalidomide were defined as decreased group, and the other 12 patients were defined as increased group. OS and PFS were compared betweem two groups. The prognostic factors were examined in the univariate and multivariate analysis, respectively. Results The median survival time,one-year survival rate and three-year survival rate of treatment group and untreatment group were 17.0 months,59.4%,31.5% and 18.7 months,56.4%,28.6%, respectively; There was no significant difference between treated group and untreated group. The median survival time,one-year survival rate and three-year survival rate of decreased group and increased group were 19.7 months, 65.0%, 42.1% and 10.7 months, 43.3%, 8.3%, respectivley; The decreased group had longer OS and PFS than increased group(χ2=4.345,4.157,P<0.05). Multivariate analysis demonstrated that clinical staging was prognostic factor on OS, not sex and tumor location.Conclusions Thalidomide combined with radiotherapy is associated with longer OS and PFS in patients with esophageal carcinoma,especially for patients with VEGF decreasing. |
| HTML View Full Text View/Add Comment Download reader |
| Close |
|
|
|
